Search results
Results from the WOW.Com Content Network
The epileptic seizure in the vast majority of pediatric epilepsy patients is ephemeral, and symptoms typically subside on their own after the seizure comes to an end, but some children experience what is known as a “seizure cluster," in which the first seizure is followed by a second episode approximately six hours later.
Therefore, almost all new epilepsy drugs are initially approved only as adjunctive (add-on) therapies. Patients whose epilepsy is uncontrolled by their medication (i.e., it is refractory to treatment) are selected to see if supplementing the medication with the new drug leads to an improvement in seizure control.
It is recommended by the World Health Organization (WHO) for the treatment of certain types of epilepsy in developing countries. [8] In the developed world, it is commonly used to treat seizures in young children, [9] while other medications are generally used in older children and adults. [10] It is also used for veterinary purposes. [11]
Vigabatrin reduced cholecystokinin tetrapeptide-induced symptoms of panic disorder, in addition to elevated cortisol and ACTH levels, in healthy volunteers. [12]Vigabatrin is also used to treat seizures in succinic semialdehyde dehydrogenase deficiency (SSADHD), which is an inborn GABA metabolism defect that causes intellectual disability, hypotonia, seizures, speech disturbance, and ataxia ...
Treatment depends generally on the underlying cause of the seizure if it is provoked. anti-epileptic drugs are also administered. Neonatal seizures that are provoked (due to a secondary cause) usually resolve in the neonatal period when the secondary cause is treated. Neonates with epilepsy syndromes often have seizures later in life. [4] It ...
A 2022 systematic review of the literature has found some evidence to support that a ketogenic diet or modified Atkins diet can be helpful in the treatment of epilepsy in some infants. [168] These types of diets may be beneficial for children with drug-resistant epilepsy; the use for adults remains uncertain. [6]
Benign infantile epilepsy (BIE), also known as benign infantile seizures (BIS), is an epilepsy syndrome of which several forms have been described. The International League Against Epilepsy (ILAE) classify two main forms of the syndrome (familial and nonfamilial) [ 1 ] though several other forms have been described in the academic literature.
Eslicarbazepine acetate (ESL), sold under the brand names Aptiom and Zebinix among others, is an anticonvulsant medication approved for use in Europe and the United States as monotherapy or as additional therapy for partial-onset seizures epilepsy. [6] [4] [3] Similarly to oxcarbazepine, ESL behaves as a prodrug to (S)-(+)-licarbazepine. [7]